Protease‐activated receptor‐mediated platelet aggregation in acute coronary syndrome patients on potent P2Y12 inhibitors

Figure 1. Platelet aggregation following stimulation with (A) ADP, (B) protease‐activated receptor (PAR)‐1 agonist SFLLRN, or (C) PAR‐4 agonist AYPGKF in patients receiving prasugrel or ticagrelor. The boundaries of the box show the lower and upper quartile of data, and the line inside the box represents the median. Whiskers are drawn from the edge of the box to the highest and lowest values that are outside the box but within 1.5 times the box length. AU, aggregation units; MEA, multiple electrode aggregometry

Figure 2. Platelet aggregation following stimulation with (A) ADP and the protease‐activated receptor (PAR)‐1 agonist SFLLRN, (B) ADP and the PAR‐4 agonist AYPGKF, and (C) the PAR‐1 and PAR‐4 agonists SFLLRN and AYPGKF, respectively, in patients receiving prasugrel (blue circles) and in patients receiving ticagrelor (red circles). Cutoff values for high on‐treatment residual platelet reactivity to ADP 20 and for normal platelet aggregation in response to SFLLRN and AYPGKF (data from healthy controls as published previously)18 are represented by the dotted lines. AU, aggregation units